ALNEV.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:05):

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France...

Stats
Dzisiejszy wolumen	26 215.00
Średni wolumen	8 651.00
Kapitalizacja rynkowa	107 404
EPS	0 ( 2019-10-02 )
Last Dividend	0 ( N/A )
Next Dividend	0 ( N/A )
P/E	0
ATR14	0.00400 (1.60%)

Neovacs SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neovacs SA Finanse

Annual	2022
Przychody:	1 112.00
Zysk brutto:	-3.43M (-308 866.37 %)
EPS:	-117.60

FY	2022
Przychody:	1 112.00
Zysk brutto:	-3.43M (-308 866.37 %)
EPS:	-117.60

FY	2021
Przychody:	22 595.00
Zysk brutto:	-462 306 (-2 046.05 %)
EPS:	-7 841.13

FY	2020
Przychody:	30 142.00
Zysk brutto:	-89 853.00 (-298.10 %)
EPS:	-4 068.95

Financial Reports:

No articles found.

Neovacs SA

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.